



Medication Audit Checklist

Duloxetine (Cymbalta®)

PEFC Approved: August 2019

Reviewer:	Date:
Drug:	Dose:

Does this audit require a physician review?

Yes

No

Audit Information:

Audit #:

Patient Information

Patient #:	Admit Date:
Prescriber:	Attending:

Indications:

Does the indication require a physician review?

Yes

No

Note which indication(s) are present:

Anxiety Disorders	
Chronic Musculoskeletal Pain	
Depressive Disorders	

Indications: (continued)

Diabetic Peripheral Neuropathic Pain (DPNP)	
Fibromyalgia	

Contraindications - Absolute:

Does this require a physician review?	Comments	Yes	No
Chronic liver disease or cirrhosis			
Duloxetine initiation in a patient who is being treated with MAOIs such as linezolid or intravenous methylene blue (increased risk of serotonin syndrome)			
Duloxetine within 14 days of stopping an MAOI intended to treat psychiatric disorders			
Heavy alcohol use			
History of anaphylactic reaction or similarly severe significant hypersensitivity to the medication prescribed			
Monoamine Oxidase Inhibitors (MAOIs)—MAOIs intended to treat psychiatric disorders with duloxetine or within 5 days of stopping treatment with duloxetine (increased risk of serotonin syndrome)			
Renal impairment, severe (GFR < 30 mL/min)			
Uncontrolled narrow-angle glaucoma			

Contraindications - Relative:

Does this require a physician review?	Comments	Yes	No
Pregnancy/nursing mothers			

Patient Monitoring - Parameters:

Does this require a physician review?	Comments	Yes	No
Height and weight – baseline, monthly and as clinically indicated (children, adolescents)			
Hepatic function—baseline and as clinically indicated			
Measure blood pressure before starting treatment and periodically throughout treatment			
Monitor for emergence of suicidal ideation or behavior			
Pregnancy test—baseline and as clinically indicated			
Sodium level in high-risk patients (e.g., older than 65 years, previous history of antidepressant-induced hyponatremia, low body weight, concomitant use of thiazides or other hyponatremia-inducing agents, experiencing symptoms of hyponatremia), baseline, 4 weeks and as clinically indicated			

Patient Monitoring - Dosing:

Does this require a physician review?	Comments	Yes	No
See HHSC Psychiatric Drug Formulary for dosage guidelines.			
Exceptions to maximum dosage must be justified as per medication rule.			